Synovial Fibroblast 1: Secretion response of primary human synovial fibroblast samples from one healthy and one rheumatoid arthritis donor to a panel of 10 stimuli and 10 small molecule inhibitors - Dataset (ID:20233)
- Detail
- Small Molecules Studied
- Primary Cells Studied
- Proteins Studied
- Unclassified Perturbagens Studied
- Data Columns
- Results
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Protein Stimulus | Other Stimulus | Stimulus Concentration | Stimulus Conc Unit | ExpPlate | Measured Protein | Measured Protein MFI (a.u.) | Bead Count |
---|---|---|---|---|---|---|---|---|---|---|---|
N2586 | IKK16 | 2.0 | uM | IL-6 | 100 | ug/mL | 3 | IL-16 | 16.5 | 54 | |
N2586 | Sigma A6730 | 3.0 | uM | 3 | IL-16 | 22.0 | 66 | ||||
RA2159 | IL-1 alpha | 100 | ng/mL | 3 | IL-16 | 18.0 | 50 | ||||
RA2159 | PD184352 | 0.1 | uM | IL-1 alpha | 100 | ng/mL | 3 | IL-16 | 21.0 | 69 | |
RA2159 | Lestaurtinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 3 | IL-16 | 19.0 | 62 | |
RA2159 | Ruxolitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 3 | IL-16 | 19.0 | 63 | |
RA2159 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 3 | IL-16 | 23.0 | 68 | |
RA2159 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 3 | IL-16 | 22.0 | 61 | |
RA2159 | PI103 | 0.1 | uM | 3 | IL-16 | 17.0 | 57 | ||||
N2586 | IL-1 alpha | 100 | ng/mL | 3 | IL-16 | 22.0 | 76 | ||||
N2586 | PD184352 | 0.1 | uM | IL-1 alpha | 100 | ng/mL | 3 | IL-16 | 23.0 | 59 | |
N2586 | Lestaurtinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 3 | IL-16 | 21.0 | 63 | |
N2586 | Ruxolitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 3 | IL-16 | 21.0 | 63 | |
N2586 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 3 | IL-16 | 18.0 | 73 | |
N2586 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 3 | IL-16 | 19.0 | 71 | |
N2586 | PI103 | 0.1 | uM | 3 | IL-16 | 19.5 | 58 | ||||
0 | IL-16 | 22.0 | 55 | ||||||||
RA2159 | TNF-a | 100 | ng/mL | 3 | IL-16 | 27.5 | 54 | ||||
RA2159 | PD184352 | 0.1 | uM | TNF-a | 100 | ng/mL | 3 | IL-16 | 20.0 | 66 | |
RA2159 | Lestaurtinib | 0.3 | uM | TNF-a | 100 | ng/mL | 3 | IL-16 | 19.0 | 60 | |
RA2159 | Ruxolitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 3 | IL-16 | 14.0 | 48 | |
RA2159 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 3 | IL-16 | 17.0 | 63 | |
RA2159 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 3 | IL-16 | 20.0 | 61 | |
RA2159 | EO1428 | 1.0 | uM | 3 | IL-16 | 20.0 | 31 | ||||
N2586 | TNF-a | 100 | ng/mL | 3 | IL-16 | 18.0 | 65 |